Galena Biopharma Presents Positive Interim Safety Data on the NeuVax™ (nelipepimut-S) Clinical Trial in Combination with Trastuzumab in High-Risk HER2 3+ Patients at the AACR Annual Meeting 2017
04 avr. 2017 07h05 HE
|
Galena Biopharma, Inc.
SAN RAMON, Calif., April 04, 2017 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (NASDAQ:GALE), a biopharmaceutical company developing hematology and oncology therapeutics that address unmet medical...
Galena Biopharma Presents Positive Final GALE-301 (E39) Phase 1/2a Clinical Trial Data
17 mars 2017 07h05 HE
|
Galena Biopharma, Inc.
SAN RAMON, Calif., March 17, 2017 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (NASDAQ:GALE), a biopharmaceutical company developing hematology and oncology therapeutics that address unmet medical...
Galena Biopharma Reports Fourth Quarter and Year End 2016 Financial Results and Provides a Corporate Update
15 mars 2017 16h15 HE
|
Galena Biopharma, Inc.
SAN RAMON, Calif., March 15, 2017 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (NASDAQ:GALE), a biopharmaceutical company developing hematology and oncology therapeutics that address unmet medical...
Galena Biopharma Engages Canaccord Genuity to Advise on Strategic Alternatives
09 mars 2017 07h05 HE
|
Galena Biopharma, Inc.
SAN RAMON, Calif., March 09, 2017 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (NASDAQ:GALE), a biopharmaceutical company developing hematology and oncology therapeutics that address unmet medical...
Galena Biopharma Board of Directors Appoints Stephen F. Ghiglieri as Interim Chief Executive Officer
21 févr. 2017 16h10 HE
|
Galena Biopharma, Inc.
SAN RAMON, Calif., Feb. 21, 2017 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (NASDAQ:GALE), a biopharmaceutical company developing hematology and oncology therapeutics that address unmet medical...
Galena Biopharma Announces Closing of Public Offering of Common Stock and Warrants
13 févr. 2017 16h30 HE
|
Galena Biopharma, Inc.
SAN RAMON, Calif., Feb. 13, 2017 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (NASDAQ:GALE), a biopharmaceutical company developing hematology and oncology therapeutics that address unmet medical...
Galena Biopharma Announces Pricing of Public Offering of Common Stock and Warrants
08 févr. 2017 08h30 HE
|
Galena Biopharma, Inc.
SAN RAMON, Calif., Feb. 08, 2017 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (NASDAQ:GALE), a biopharmaceutical company developing hematology and oncology therapeutics that address unmet medical...
Galena Biopharma Announces Proposed Public Offering of Common Stock and Warrants
07 févr. 2017 16h10 HE
|
Galena Biopharma, Inc.
SAN RAMON, Calif., Feb. 07, 2017 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (NASDAQ:GALE), a biopharmaceutical company developing hematology and oncology therapeutics that address unmet medical...
Galena Biopharma Reports Positive Outcome from the Data Safety Monitoring Board on the Two NeuVax™ (nelipepimut-S) Clinical Trials in Combination with Trastuzumab
06 févr. 2017 07h05 HE
|
Galena Biopharma, Inc.
Both combination trials are deemed not futile and Data Safety Monitoring Board recommends that both trials continueInterim efficacy analysis for the low-to-intermediate (HER2 1+/2+) trial now expected...
Galena Biopharma Announces the Resignation of its President and Chief Executive Officer and the Evaluation of Strategic Alternatives
31 janv. 2017 17h00 HE
|
Galena Biopharma, Inc.
SAN RAMON, Calif., Jan. 31, 2017 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (NASDAQ:GALE), a biopharmaceutical company committed to the development and commercialization of hematology and oncology...